Lentivector immunization induces tumor antigen-specific B and T cell responses in vivo

European Journal of Immunology

Volumn 38, Issue 7, 2008, Pages 1867-1876

  Casado, Javier Garcia ^a   Janda, Jozef ^a   Wei, Joe ^b   Chapatte, Laurence ^a   Colombetti, Sara ^a   Alves, Pedro ^c   Ritter, Gerd ^d   Ayyoub, Maha ^e   Valmori, Danila ^e   Chen, Weisan ^b   Lévy, Frédéric ^a,c  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b AUSTIN HOSPITAL   (Australia)

^c SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e INSERM   (France)

Author keywords

B cell response; Lentivector; NY ESO 1; T cell response; Tumor immunology

Indexed keywords

GAMMA INTERFERON; HERMES ANTIGEN; HLA A2 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 7 RECEPTOR; L SELECTIN; LENTIVIRUS VECTOR; NY ESO 1 ANTIGEN; NY ESO 1 ANTIGEN [151-165]; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR V BETA; UNCLASSIFIED DRUG; CANCER ANTIBODY; CANCER VACCINE; CTAG1B PROTEIN, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; DRUG POTENCY; DRUG RESPONSE; EX VIVO STUDY; HUMORAL IMMUNITY; IMMUNOPHENOTYPING; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; SINGLE DRUG DOSE; T CELL DEPLETION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; TUMOR IMMUNITY; VIRUS RECOMBINANT; ANIMAL; BLOOD; GENE VECTOR; HUMAN; IMMUNIZATION; IMMUNOLOGY; LENTIVIRINAE; LYMPHOCYTE ACTIVATION; METABOLISM;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; GENETIC VECTORS; HUMANS; IMMUNIZATION; LENTIVIRUS; LYMPHOCYTE ACTIVATION; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; RECEPTORS, ANTIGEN, B-CELL; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC;

EID: 50549089314     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737923     Document Type: Article

References (37)

1. Chen, Y.-T., Scanlan, M. J., Sahin, U., Tureci, O., Gure, A. O., Tsang, S., Williamson, B. et al., A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc. Natl. Acad. Sci. USA 1997. 94: 1914-1918.
2. Jager, E., Chen, Y.-T., Drijfhout, J. W., Karbach, J., Ringhoffer, M., Jager, D., Arand, M. et al., Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J. Exp. Med. 1998. 187: 265-270.
3. Stockert, E., Jager, E., Chen, Y. T., Scanlan, M. J., Gout, I., Karbach, J., Arand, M. et al., A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J. Exp. Med. 1998. 187: 1349-1354.
4. + T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000. 60: 4499-4506.
5. Jäger, E., Nagata, Y., Gnjatic, S., Wada, H., Stockert, E., Karbach, J., Dunbar, P. R. et al., Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses. Proc. Natl. Acad. Sci. USA 2000. 97: 4760-4765.
6. + T cell responses in humans. Proc. Natl. Acad. Sci. USA 2004. 101: 10697-10702.
7. Valmori, D., Levy, F., Godefroy, E., Scotto, L., Souleimanian, N. E., Karbach, J., Tosello, V. et al., Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen. Clin. Immunol. 2007. 122: 163-172.
8. Chen, J.-L., Stewart-Jones, G., Bossi, G., Lissin, N. M., Wooldridge, L., Choi, E. M. L., Held, G. et al., Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J. Exp. Med. 2005. 201: 1243-1255.
9. Purbhoo, M. A., Sutton, D. H., Brewer, J. E., Mullings, R. E., Hill, M. E., Mahon, T. M., Karbach, J. et al., Quantifying and imaging NY-ESO-1/LAGE-1-derived epitopes on tumor cells using high affinity T cell receptors. J. Immunol. 2006. 176: 7308-7316.
10. + T lymphocytes of patients with NY-ESO-1-expressing melanoma. J. Exp. Med. 2000. 191: 625-630.
11. + T cells. Cancer Res. 2000. 60: 4946-4952.
12. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J. Immunol. 2000. 165: 1153-1159.
13. Gnjatic, S., Nishikawa, H., Jungbluth, A. A., Gure, A. O., Ritter, G., Jager, E., Knuth, A. et al., NY-ESO-1: Review of an immunogenic tumor antigen. Adv. Cancer Res. 2006. 95: 1-30.
14. Jager, E., Karbach, J., Gnjatic, S., Neumann, A., Bender, A., Valmori, D., Ayyoub, M. et al., Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc. Natl. Acad. Sci. USA 2006. 103: 14453-14458.
15. Nishikawa, H., Sato, E., Briones, G., Chen, L.-M., Matsuo, M., Nagata, Y., Ritter, G. et al., In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J. Clin. Invest. 2006. 116: 1946-1954.
16. Lotem, M., Zhao, Y., Riley, J., Hwu, P., Morgan, R. A., Rosenberg, S. A. and Parkhurst, M. R., Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors. J. Immunother. 2006. 29: 616-627.
17. + tumors. Clin. Cancer Res. 2004. 10: 2879-2890.
18. Valmori, D., Souleimanian, N. E., Tosello, V., Bhardwaj, N., Adams, S., O'Neill, D., Pavlick, A. et al., Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl. Acad. Sci. USA 2007. 104: 8947-8952.
19. + memory T cells by recombinant lentivectors. Cancer Res. 2006. 66: 1155-1160.
20. Palmowski, M. J., Lopes, L., Ikeda, Y., Salio, M., Cerundolo, V. and Collins, M. K., Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J. Immunol. 2004. 172: 1582-1587.
21. Vitiello, A., Marchesini, D., Furze, J., Sherman, L. A. and Chesnut, R. W., Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J. Exp. Med. 1991. 173: 1007-1015.
22. b transgenic mice. J. Immunol. 1999. 162: 3566-3573.
23. Chapatte, L., Servis, C., Valmori, D., Burlet-Schiltz, O., Dayer, J., Monsarrat, B., Romero, P. and Lévy, F., Final antigenic Melan-A peptides produced directly by the proteasomes are preferentially selected for presentation by HLA-A*0201 in melanoma cells. J. Immunol. 2004. 173: 6033-6040.
24. Lévy, F., Johnsson, N., Rümenapf, T. and Varshavsky, A., Using ubiquitin to follow the metabolic fate of a protein. Proc. Natl. Acad. Sci. USA 1996. 93: 4907-4912.
25. Chen, J.-L., Dunbar, P. R., Gileadi, U., Jäger, E., Gnjatic, S., Nagata, Y., Stockert, E. et al., Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL. J. Immunol. 2000. 165: 948-955.
26. Webb, A. I., Dunstone, M. A., Chen, W., Aguilar, M.-I., Chen, Q., Jackson, H., Chang, L. et al., Functional and structural characteristics of NY-ESO-1-related HLA A2-restricted epitopes and the design of a novel immunogenic analogue. J. Biol. Chem. 2004. 279: 23438-23446.
27. high) phenotype by an archaeosome adjuvant independent of TLR2. J. Immunol. 2007. 178: 2396-2406.
28. Kaech, S. M., Tan, J. T., Wherry, E. J., Konieczny, B. T., Surh, C. D. and Ahmed, R., Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 2003. 4: 1191-1198.
29. + T-cell responses to the tumor-specific antigen NY-ESO-1. J. Immunother. 2005. 28: 252-257.
30. + T cell responses. J. Clin. Invest. 2003. 111: 1673-1681.
31. Zarei, S., Abraham, S., Arrighi, J.-F., Haller, O., Calzascia, T., Walker, P. R., Kundig, T. M. et al., Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J. Virol. 2004. 78: 7843-7845.
32. Kung, S. K. P., Bonifacino, A., Metzger, M. E., Ringpis, G.-E., Donahue, R. E. and Chen, I. S. Y., Lentiviral vector-transduced dendritic cells induce specific T cell response in a nonhuman primate model. Hum. Gene Ther. 2005. 16: 527-532.
33. Dullaers, M., Meirvenne, S. V., Heirman, C., Straetman, L., Bonehill, A., Aerts, J. L., Thielemans, K. and Breckpot, K., Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. Gene Ther. 2006. 13: 630-640.
34. + T-cell responses. J. Virol. 2008. 82: 86-95.
35. + T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006. 24: 643-656.
36. Chapatte, L., Ayyoub, M., Morel, S., Peitrequin, A.-L., Lévy, N., Servis, C., Van den Eynde, B. J. et al., Processing of tumor-associated antigen by the proteasomes of dendritic cells controls in vivo T-cell responses. Cancer Res. 2006. 66: 5461-5468.
37. + T-cell responses induced by DNA immunization. J. Virol. 2000. 74: 8286-8291.